Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02624765 · ClinicalTrials.gov registry record · Phase 3
Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)
A Phase 3 study of Fetal Atrial Flutter Without Hydrops and Fetal Supraventricular Tachycardia Without Hydrops, sponsored by Edgar Jaeggi.
- Completed
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT02624765: Completed Phase 3 study of Fetal Atrial Flutter Without Hydrops and Fetal Supraventricular Tachycardia Without Hydrops, sponsored by Edgar Jaeggi.
NCT02624765 is a Phase 3 study of Fetal Atrial Flutter Without Hydrops and Fetal Supraventricular Tachycardia Without Hydrops that has completed, run by Edgar Jaeggi. The registered enrollment target is 105 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02624765, a Phase 3 study of Fetal Atrial Flutter Without Hydrops and Fetal Supraventricular Tachycardia Without Hydrops, has completed, sponsored by Edgar Jaeggi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Fetal Atrial Flutter and Supraventricular Tachycardia (FAST) Therapy Trial is a prospective multi-center trial that examines the efficacy and safety of standard prenatal antiarrhythmic treatment. Study components of FAST include three prospective sub-studies to determine the efficacy and safety of commonly used transplacental drug regimens in suppressing fetal AF without hydrops (Randomized Clinical Trial (RCT) A), SVT without hydrops (RCT B), and SVT with hydrops (RCT C). All RCTs are open label phase III trials of standard 1st line therapy, which either is started as monotherapy (no hydrops) or as dual therapy (hydrops).
Primary Outcome
Term delivery (≥37 0/7 weeks gestation) with a normal cardiac rhythm (ECG).
Conditions Studied
Interventions
- DRUG Digoxin (monotherapy)
- DRUG Sotalol (monotherapy)
- DRUG Flecainide (monotherapy)
- DRUG Digoxin (dual therapy)
- DRUG Sotalol (dual therapy)
Study Locations (20)
New York
- Morgan Stanley Children's Hospital of New York-Presbyterian - New York
- Cohen Children's Medical Center - New York
Texas
- Pediatrix Medical Services, Inc, - Austin
- Baylor College of Medicine - Houston
Ontario
- Mount Sinai Hospital - Toronto
- The Hospital for Sick Children - Toronto
Other
- UKB Universitätsklinikum BONN - Bonn
- Academic Medical Center - AMC - Amsterdam
California
- UCSF Benioff Children's Hospital - San Francisco
Colorado
- Children's Hospital of Colorado - Aurora
District of Columbia
- Children's National Health System - Washington D.C.
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2016-02 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 3 |
What the finished NCT02624765 record still lists
NCT02624765 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Fetal Atrial Flutter Without Hydrops appearing as the primary indexed condition, and to 5 interventions - of which Digoxin (monotherapy) is the first listed.
NCT02624765 names 20 study sites across 16 states, led by New York, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT02624765 about?
NCT02624765 is a clinical study titled "Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)". The Fetal Atrial Flutter and Supraventricular Tachycardia (FAST) Therapy Trial is a prospective multi-center trial that examines the efficacy and safety of standard prenatal antiarrhythmic treatment. Study components of FAST include three prospective sub-studies to determine the efficacy and safety ...
What is the current status of trial NCT02624765?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2016-02. Estimated completion is 2024-03-31.
What conditions does trial NCT02624765 study?
This clinical trial studies the following conditions: Fetal Atrial Flutter Without Hydrops, Fetal Supraventricular Tachycardia Without Hydrops, Fetal Supraventricular Tachycardia With Hydrops.
What interventions are being tested in trial NCT02624765?
The interventions under investigation include: Digoxin (monotherapy) (DRUG), Sotalol (monotherapy) (DRUG), Flecainide (monotherapy) (DRUG), Digoxin (dual therapy) (DRUG), Sotalol (dual therapy) (DRUG).
Who is sponsoring clinical trial NCT02624765?
This trial is sponsored by Edgar Jaeggi, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02624765 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02624765's enrollment target sits among peer trials
105 1670th of 2000 higher than 330 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia